Investigational Drug Information for Mavoglurant
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Mavoglurant?
Mavoglurant is an investigational drug.
There have been 6 clinical trials for Mavoglurant.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 17th 2017.
The most common disease conditions in clinical trials are Alcoholism, Cocaine-Related Disorders, and Syndrome. The leading clinical trial sponsors are Yale University, Novartis Pharmaceuticals, and Elizabeth Berry-Kravis.
There are fifty-five US patents protecting this investigational drug and five hundred and eighty-five international patents.
Summary for Mavoglurant
| US Patents | 55 |
| International Patents | 585 |
| US Patent Applications | 128 |
| WIPO Patent Applications | 65 |
| Japanese Patent Applications | 23 |
| Clinical Trial Progress | Phase 2 (2017-08-17) |
| Vendors | 30 |
Recent Clinical Trials for Mavoglurant
| Title | Sponsor | Phase |
|---|---|---|
| Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant | Yale University | Early Phase 1 |
| Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN | Yale University | Early Phase 1 |
| Mavoglurant in Alcohol Drinking | Yale University | Phase 1 |
Clinical Trial Summary for Mavoglurant
Top disease conditions for Mavoglurant
Top clinical trial sponsors for Mavoglurant
US Patents for Mavoglurant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Mavoglurant | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Mavoglurant | See Plans and Pricing | Methods of treating sleep disorders | Melior Pharmaceuticals II, LLC (Exton, PA) | See Plans and Pricing |
| Mavoglurant | See Plans and Pricing | Composition and method for treating neurological disease | Osmotica Kereskedelmi es Szolgaltato Korlatolt Feleossegu Tarsasag (Budapest, HU) | See Plans and Pricing |
| Mavoglurant | See Plans and Pricing | Composition and method for treating neurological disease | Osmotica Kereskedelmi es Szolgaltato Korlatolt Felelossegu Tarsasag (Budapest, HU) | See Plans and Pricing |
| Mavoglurant | See Plans and Pricing | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | See Plans and Pricing | |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Mavoglurant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Mavoglurant | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| Mavoglurant | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| Mavoglurant | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| Mavoglurant | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
| Mavoglurant | European Patent Office | EP3981392 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
